Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations

INTRODUCTION: Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or exon 21 epidermal growth factor receptor mutation (EGFRm). This is an observational study investigating epidemiology, clinical features and tre...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Frega, Stefano, Lorenzi, Martina, Fassan, Matteo, Indraccolo, Stefano, Calabrese, Fiorella, Favaretto, Adolfo, Bonanno, Laura, Polo, Valentina, Zago, Giulia, Lunardi, Francesca, Attili, Ilaria, Pavan, Alberto, Rugge, Massimo, Guarneri, Valentina, Conte, PierFranco, Pasello, Giulia
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2017
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464815/
https://ncbi.nlm.nih.gov/pubmed/28427238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15945
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg